Compare D Wave Quantum Inc (QBTS) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D Wave Quantum Inc vs GeneDx Holdings Corp — how do they compare? D Wave Quantum Inc trades at $17.35 (market cap $6.59B), while GeneDx Holdings Corp trades at $61.39 (market cap $1.83B). The key difference: D Wave Quantum Inc is far larger — about 3.6× GeneDx Holdings Corp's market cap. Which is the better fit depends on your goals.
| QBTS | WGS | |
|---|---|---|
Market Cap | $6.59B | $1.83B |
Sector | Technology | Technology |
52-Week High | $44.78 | $167.51 |
52-Week Low | $12.98 | $34.51 |
Enterprise Value | $6.05B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QBTS trades at $16.73, showing no change in the last 24 hours. The stock is technically bearish with key support at $16 and resistance at $17. Fundamentally, the company reported a net loss of $355.06 million on $24.59 million revenue in 2025, with a negative net income margin of -2,957.23%. Recent news highlights D-Wave's dual-platform quantum computing approach and a recent transfer of its stock listing to Nasdaq (Business Wire, July 14, 2026).
Despite unanimous analyst buy ratings and a $39.86 consensus price target implying significant upside, QBTS faces substantial execution risks. High cash burn, negative profitability, and intense competition in the emerging quantum computing sector present challenges. The stock's appeal hinges on future revenue growth materializing from current commercial partnerships and technological advancements.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
